Products - Plastic Surgery Practice https://plasticsurgerypractice.com/treatment-solutions/products/ Plastic Surgery Practice is the brand that 12,000 plastic surgeons rely on for the latest information on the clinical innovations, practice-management trends, emerging products and technologies, and news stories that drive their field. With well-thought-out articles by leading practitioners, PSP gets to the core of the most complex issues in plastic surgery, including controversial new treatments, the use of highly technical equipment, and physician-patient interactions. Wed, 26 Mar 2025 15:34:58 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.2 Alma Launches Next-Gen Harmony System for Multi-Tech Aesthetic Treatments https://plasticsurgerypractice.com/treatment-solutions/products/lasers-ipl/alma-launches-next-gen-harmony-system-multi-tech-aesthetic-treatments/ https://plasticsurgerypractice.com/treatment-solutions/products/lasers-ipl/alma-launches-next-gen-harmony-system-multi-tech-aesthetic-treatments/#respond Wed, 26 Mar 2025 15:33:47 +0000 https://plasticsurgerypractice.com/?p=121686 Powered by five integrated technologies, the multi-platform is designed to support a range of treatments for various skin types and conditions.

Alma Lasers, a Sisram Medical company specializing in energy-based medical and aesthetic solutions, announced the debut of the latest edition of its aesthetics platform, Alma Harmony, featuring upgrades to offer more treatment possibilities.

The new platform is powered by five technologies, integrated to provide a range of treatments for almost any indication or skin type: 

  • the Q-Switch laser stimulates collagen and treats pigmentation by targeting dermal layers, 
  • the fractional ablative laser creates pixel-sized perforations in the skin, inducing rejuvenation while preserving surrounding tissues for quicker recovery, 
  • intense pulsed light offers a balanced approach to aesthetic improvements across a range of patient skin types and concerns, 
  • non-ablative lasers rejuvenate skin by promoting collagen production from within the dermis, and 
  • the green diode laser treats vascular lesions, aiming to enhance both efficacy and safety.

With up to a 45% increase in energy*, the new multiplatform offers the capabilities of standalone lasers in a single platform. This enhanced energy enables practitioners to address the diverse needs of patients—across different ages, skin types, and treatment goals—and to provide clinically proven treatments for the most in-demand categories, such as skin resurfacing, skin rejuvenation and tightening, hair removal, acne and acne scars, vascular lesions, pigmented lesions, and tattoo removal, to name a few.

Updated Platform Focuses on Workflow Efficiency and Multi-Technology Integration

Designed to enhance efficiency, simplicity, and ease of use, the new Alma Harmony includes automated features such as customizable presets, ergonomically designed applicators, and functionality that makes operation seamless.

“The majority of the skin conditions we treat need more than one light or laser at the same time in the same session, and to work with a platform where you can have very easy connection enables us to do really personalized treatments with multiple wavelengths, multiple lights, to achieve the depth and the chromophore we want to target to achieve good results in those specific diseases,” says Pablo Naranjo, MD, PhD, medical director of Elite Laser Clinic & Laser Unit at NISA Hospital, Madrid, Spain, in a release.  “The new Alma Harmony allows me to have the same power as standalone lasers in an all-in-one platform and to achieve the next level of results with my patients.” 

Lior Dayan, CEO of Alma, adds in a release, “Alma Harmony sets a new standard for functionality, versatility, and performance. The new flagship multiplatform allows professionals to combine synergetic technologies to effectively treat a wide range of aesthetic concerns, addressing the growing consumer demand for combination procedures for longer-lasting results and a shorter recovery, while enhancing both practitioner efficiency and patient experience to unprecedented levels.”

Aiming to support clinic business offerings and increase visibility, Alma is launching the new platform together with Harmony Bio-Boost, a branded treatment tackling skin rejuvenation.

Harmony Bio-Boost, currently exclusive to Alma Harmony users, harnesses the skin’s natural healing process and leverages the power of biostimulation to deliver results. This treatment is designed to improve skin tone and texture and serves as a catalyst for collagen renewal and elastin production that continues to work up to six months** post-treatment.

*Compared to Harmony XL PRO using specific parameters 

**After a non-ablative fractional laser treatment.

Photo caption: Alma Harmony

Photo credit: Alma Lasers

The Synergy of Light and Lotion: How Skincare is Transforming Laser Aesthetics
]]> https://plasticsurgerypractice.com/treatment-solutions/products/lasers-ipl/alma-launches-next-gen-harmony-system-multi-tech-aesthetic-treatments/feed/ 0 The Synergy of Light and Lotion: How Skincare is Transforming Laser Aesthetics https://plasticsurgerypractice.com/treatment-solutions/cosmetics-skin-care/the-synergy-of-light-and-lotion-how-skincare-is-transforming-laser-aesthetics/ Wed, 19 Feb 2025 16:46:46 +0000 https://plasticsurgerypractice.com/?p=121387

The Evolving Landscape of Aesthetic Procedures

In the world of aesthetic medicine, lasers and energy-based devices have long been the gold standard for skin rejuvenation. From IPL (Intense Pulsed Light) to fractional CO₂ lasers, these technologies have consistently delivered impressive results in treating pigmentation, vascular lesions, and textural irregularities. Yet, as the field advances, practitioners are beginning to recognize a surprising ally in enhancing these outcomes: medical-grade skincare.

Traditionally seen as a supplementary component, skincare products were often relegated to post-procedural care, aimed at soothing the skin or maintaining results. However, emerging research is challenging this notion, suggesting that the integration of targeted skincare both before and during laser treatments could significantly amplify patient outcomes.

When Lasers Meet Lotions: A New Clinical Paradigm

A recent study led by Dr. Sherrif Ibrahim, Associate Professor of Dermatology at Rochester Medical Center and a procedural dermatologist specializing in aesthetic and skin cancer surgeries, has brought new attention to this evolving synergy. In collaboration with Sciton—a leading manufacturer of laser and light-based technologies—and Jan Marini Skin Research, Dr. Ibrahim conducted a study that explored the impact of combining broadband light (BBL) treatments with a structured skincare regimen.

The study divided patients into two groups:

  • Group One received six weeks of pre-treatment with Jan Marini’s Skincare Management System, followed by two BBL sessions.
  • Group Two underwent three BBL treatments without any changes to their existing skincare routines.

The hypothesis was simple: Could pre-treatment and concurrent use of professional-grade skincare enhance the results typically achieved by BBL alone? The findings were anything but simple—and they have the potential to reshape aesthetic protocols.

The Surprising Results: Skincare as a Clinical Enhancer

Dr. Ibrahim, a self-proclaimed “laser guy” and initial skeptic of skincare’s impact on procedural outcomes, admitted to being surprised by the results. The group that combined skincare with two BBL treatments achieved outcomes comparable to, and in some cases better than, those who had undergone three BBL sessions without skincare intervention. Metrics such as elasticity, pigmentation, pore size, and overall skin texture showed marked improvements across both groups, but the skincare group reached these endpoints more efficiently.

“What we found was not just additive—it was synergistic,” Dr. Ibrahim noted during the webinar. “The combination of skincare and BBL didn’t just yield better skin; it delivered those results faster and more effectively than we anticipated.”

This synergy suggests that high-quality, evidence-based skincare may prime the skin in ways that enhance its responsiveness to energy-based treatments. The implications of this finding could ripple through aesthetic practices, prompting a reevaluation of pre-treatment protocols that have traditionally focused solely on device settings and post-care. 

The Science Behind the Synergy

The synergy between advanced skincare and laser treatments isn’t just anecdotal—it’s grounded in solid dermatological science. When skin is properly prepped and supported at the cellular level, its capacity to respond to energy-based treatments like broadband light (BBL) is significantly enhanced. This isn’t just about surface hydration or soothing post-procedure redness; it’s about fundamentally altering the skin’s biological environment to optimize its regenerative response.

In Dr. Ibrahim’s study, the Jan Marini Skincare Management System played a pivotal role, incorporating clinically validated ingredients that target key skin functions. Here’s how these components work together to enhance laser outcomes:

  • Retinoids (e.g., Retinyl Palmitate): Stimulate fibroblast activity, boosting collagen and elastin production. A primed dermal matrix allows BBL’s photothermal energy to penetrate more effectively, enhancing both immediate and long-term skin rejuvenation.
  • Antioxidants (e.g., Vitamin C, Green Tea Extract): Reduce oxidative stress, which is a major contributor to post-laser inflammation and delayed healing. By minimizing free radical damage, antioxidants help speed recovery and decrease redness and swelling after treatments.
  • Hyaluronic Acid & Peptides: Strengthen the skin barrier, improving hydration and resilience. A robust barrier reduces transepidermal water loss (TEWL), minimizing post-procedural dryness and irritation, and enabling skin to better tolerate laser energy.

The cumulative effect of these ingredients creates a skin environment that’s biologically “ready” to maximize the benefits of BBL, leading to superior aesthetic outcomes with fewer sessions and faster recovery.

This isn’t just theoretical. Similar findings have been echoed in dermatological research. A 2021 publication in the Journal of Cosmetic Dermatology demonstrated that pre-treatment with a topical regimen containing peptides and antioxidants significantly improved recovery and outcomes after fractional laser treatments. Patients experienced quicker healing, reduced redness, and enhanced overall skin texture compared to those treated with lasers alone.

The takeaway? Skincare isn’t just an afterthought—it’s a critical part of the treatment. As both research and clinical experience continue to align, integrating skincare into laser protocols is quickly becoming the new standard in aesthetic medicine.

From Skepticism to Standard of Care?

Historically, many in the aesthetic field—including seasoned dermatologists and plastic surgeons—have been skeptical of the role skincare could play in enhancing procedural outcomes. Dr. Sherrif Ibrahim himself candidly admitted he didn’t give much thought to pre-treatment regimens before this study. “I thought the lasers did such a good job on their own, there wasn’t much point in adding skincare,” he remarked during the webinar. For many practitioners, this sentiment rings true. After all, when you’re working with state-of-the-art devices like Sciton’s BBL HERO, it’s easy to assume the technology alone is sufficient.

However, the results of this study challenged that assumption. Not only did the skincare group match the outcomes of the additional BBL session, but patients also reported greater satisfaction and faster visible improvements. “I was a skincare skeptic,” Dr. Ibrahim admitted, “but the data doesn’t lie. The synergy was undeniable.”

This shift in perspective isn’t isolated to Dr. Ibrahim’s practice. As more clinicians are exposed to data supporting the integration of skincare into procedural protocols, there’s a growing movement toward making it a standard part of treatment plans. It’s not just about achieving better results—it’s about optimizing the entire patient experience. Reduced treatment sessions mean less time in the clinic for patients, faster achievement of aesthetic goals, and, in many cases, lower overall costs.

For practitioners, embracing skincare as part of pre-treatment isn’t just about patient satisfaction—it’s also about enhancing the efficiency and reputation of their practice. Offering comprehensive care that includes both cutting-edge technology and evidence-based topical treatments positions a practice at the forefront of aesthetic medicine. It signals to patients that the clinic isn’t just about devices; it’s about delivering holistic, science-backed solutions.

Is Skincare the Missing Link in Your Laser Treatments?

Interested in how skincare can amplify your laser treatment results? This article highlights Dr. Sherrif Ibrahim’s surprising study, but there’s more to uncover. For a deeper dive into the data, real patient outcomes, and Dr. Ibrahim’s expert insights, don’t miss the full webinar.
Watch the Full Webinar Here

Implications for Aesthetic Practices

The clinical implications of Dr. Ibrahim’s study are clear, but the business and operational impacts for aesthetic practices are equally compelling. Integrating a structured skincare regimen like the Jan Marini Skincare Management System into treatment protocols offers a multi-faceted advantage that extends beyond improved patient outcomes.

First, there’s the matter of patient engagement and satisfaction. Patients who actively participate in their care—whether through at-home skincare routines or lifestyle adjustments—tend to feel more invested in their treatment outcomes. In Dr. Ibrahim’s study, patients in the skincare group reported feeling more empowered and engaged with their treatment process. This sense of ownership often translates to higher patient satisfaction, better compliance with post-treatment protocols, and increased likelihood of returning for additional procedures. In fact, many of Dr. Ibrahim’s patients requested to continue using the Jan Marini products after the study ended, highlighting the lasting impression that effective skincare can leave.

Second, there’s the economic benefit. Skincare products represent a low-overhead, high-margin addition to any aesthetic practice. While energy-based treatments like BBL come with significant equipment costs, maintenance fees, and time-intensive sessions, skincare products offer a relatively passive revenue stream. Dr. Ibrahim noted that selling the Jan Marini Skincare Management System, which retails for around $350 with a wholesale cost of $175, provided a direct and consistent source of profit. Multiply this across a patient base returning for refills several times a year, and the numbers quickly add up.

Moreover, combining skincare with treatments can optimize practice efficiency. By achieving better results with fewer sessions, practitioners can open up appointment slots for new patients or more complex procedures. This increases patient throughput without compromising the quality of care, ultimately leading to higher revenue per hour of clinic time.

Finally, offering comprehensive care enhances a practice’s reputation. In today’s competitive aesthetic landscape, patients are looking for providers who offer more than just the basics. They want cutting-edge technology, personalized treatment plans, and holistic care that addresses their skin’s needs from every angle. By incorporating skincare into treatment protocols, practitioners signal that they’re at the forefront of both technology and dermatological science.

In Dr. Ibrahim’s words, “Patients came in expecting lasers to do all the work. But when they saw the difference that skincare made, they were blown away. It wasn’t just about looking better—it was about feeling like they had control over their results.”

The Future of Combination Therapy in Aesthetic Medicine

Dr. Ibrahim’s study is a testament to the evolving nature of aesthetic medicine, where the boundaries between devices, products, and procedures are increasingly blurred. As more research emerges supporting the synergistic effects of skincare and laser treatments, the industry may see a shift towards more holistic, integrated approaches to patient care.

For now, the message is clear: Skincare is no longer just a maintenance tool—it’s a performance enhancer. And for practitioners looking to stay at the forefront of aesthetic innovation, embracing this synergy could be the key to unlocking superior patient outcomes.

References

  • Smith, A. et al. (2020). The Role of Antioxidant Serums in Enhancing Fractional Laser Resurfacing Outcomes. Lasers in Surgery and Medicine, 52(8), 707-714.
  • Johnson, K. et al. (2018). Pre-Treatment Skincare in Dermatologic Procedures: A Meta-Analysis. Dermatologic Surgery, 44(3), 401-410.
  • Ibrahim, S. (2024). Combining Broadband Light (BBL) with Skincare: A Study on Enhanced Outcomes. Physician Webinar Series, Jan Marini Skin Research.

Sponsored By

Medqor is committed to protecting and respecting your privacy. We may contact you about our products and services or share information with sponsorship partners, as well as other content that may be of interest to you. By submitting your information, you consent to us contacting you for this purpose in accordance with our privacy policy.

For further information, please check out our privacy policy here

]]> Establishment Labs Launches Preservé for Aesthetic Breast Augmentation in Brazil https://plasticsurgerypractice.com/client-objectives/aesthetics/breast-augmentation/enhancements/establishment-labs-launches-preserve-for-aesthetic-breast-augmentation-in-brazil/ Wed, 19 Feb 2025 00:30:00 +0000 https://plasticsurgerypractice.com/?p=121439 Summary: Establishment Labs has launched Preservé in Brazil, expanding its minimally invasive breast aesthetics platform with a focus on breast tissue preservation for more natural and stable results. Utilizing proprietary surgical tools and Ergonomix2 implants, Preservé aims to improve safety, recovery, and long-term outcomes, with a global rollout planned.

Key Takeaways:

  • Preservé builds on the technology of Mia Femtech to offer a less invasive alternative to traditional breast augmentation, enhancing safety, recovery, and aesthetic outcomes.
  • The new breast tissue preservation platform could expand the pool of women considering augmentation while driving growth and profitability for Establishment Labs.
  • After debuting in Brazil, Preservé will be introduced in other markets worldwide, though it is not yet approved for commercial use in the U.S.

Establishment Labs Holdings Inc, a global medical technology company focused on women’s health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé in Brazil, the first country in its global rollout. Preservé is the second product in the company’s minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech, Establishment Labs’ minimally invasive experience.

Addressing Patient Concerns with Minimally Invasive Solutions

“These are not small innovations, this is an entirely new era for aesthetic breast surgery,” said Juan José Chacón-Quirós, founder and CEO of Establishment Labs. “Whereas Mia made minimally invasive breast aesthetics possible for women looking for a one to two cup enhancement, Preservé allows less invasive breast surgery for the day-to-day breast augmentation patient.”

“Historically, many women have not been convinced by traditional methods and legacy techniques,” Chacón-Quirós continued. “With Mia and Preservé, we have solutions that address these concerns. The technology platform of breast tissue preservation allows plastic surgeons to create natural results with less disruption of the patient’s breast tissue. By improving safety profiles, recovery times, and achieving the breast aesthetic patients are looking for, breast augmentation may now be possible for women that otherwise never would have considered it—as well as making the decision easier for many who were already considering. After Brazil, Preservé will rollout globally over the next few years, and this should contribute to top line growth and profitability.”

Regulatory Status and U.S. Availability

The medical devices used in Preservé are not yet approved for commercial distribution in the United States.

Breast Augmentation with Tissue Preservation

According to the company, Preservé was designed to preserve breast tissue during aesthetic breast surgery, maintaining the structural anatomy and function of the breast for more stable and natural outcomes when compared to traditional breast augmentation. Preservé reportedly leverages Establishment Labs’ proprietary minimally invasive surgical tools coupled with the Ergonomix2 implants, which feature the patented SmoothSilk surface, designed for enhanced biocompatibility and softness; in addition, their shape adapts as the body changes position. Preservé is intended for primary augmentations up to four cups, hybrid augmentations, and mastopexy augmentations.

“Breast tissue preservation is a new paradigm in breast aesthetics. With less invasive breast procedures made possible by technology pioneered by Establishment Labs, we can address many of the complications that lead to reoperations,” said Dr Kamakshi Zeidler, San Francisco plastic surgeon and head of the Femtech board of Establishment Labs. “Preservé is an incredible new choice for women considering breast augmentation because it speaks to many of their aspirations, including smaller scars, quicker recovery, maintaining breast sensation, and avoiding unnecessary reoperations.”

Launch Event and Global Expansion Plans

The commercial launch of Preservé took place last weekend at the Brazilian Breast Meeting in Rio de Janeiro with over 300 surgeons in attendance and included live surgery and academic sessions. This year additional launches of Preservé are planned around the world.

Photo: ID 136326144 © Chernetskaya | Dreamstime.com

]]> New Post-Surgical Garments Offer Compression and Pain Relief https://plasticsurgerypractice.com/treatment-solutions/products/new-post-surgical-garments-combine-compression-and-pain-relief/ Thu, 21 Nov 2024 20:45:29 +0000 https://plasticsurgerypractice.com/?p=121205 Summary: Clothing 2.0 and The Marena Group LLC have partnered to offer reusable post-surgical garments infused with pain-relieving ingredients to support recovery for aesthetic and plastic surgery patients.

Key Takeaways

  • New Post-Surgical Garments: Clothing 2.0 and The Marena Group have developed reusable garments with embedded pain-relieving ingredients for post-surgical recovery.
  • Integration of Pain Relief: The garments combine compression with pain relief to support recovery after aesthetic and plastic surgery.
  • Focus on Practicality: The design addresses challenges in patient compliance by incorporating pain relief directly into wearable garments.

———————————————————————————————————————————————————————

Clothing 2.0, a company specializing in delivering natural pain-relief through clothing, and The Marena Group LLC, a provider of medical-grade post-surgical compression garments, have partnered to introduce a new option for patients recovering from aesthetic and plastic surgery. The collaboration introduces post-surgical garments infused with over-the-counter pain-relieving ingredients. These garments are reusable, laundry-safe, and designed to support recovery.

“This partnership reflects our commitment to improving patient recovery through innovative products that merge textiles with natural active ingredients. We’ve always prioritized patient care, and this advancement takes our efforts to the next level, ” says Dale Clendon, CEO of The Marena Group.

Enhancing Post-Surgical Recovery

Colin Marafko, chief commercial officer at Marena, also spoke out about the partnership, commenting: “Our exclusive alliance with Clothing 2.0 allows us to deliver natural pain relief safely and effectively through our high-quality recovery garments. This breakthrough underscores Marena’s legacy of innovation and sets a new standard for post-surgical care.”

Jordan Schindler, CEO and founder of Clothing 2.0, adds that patient compliance is a significant hurdle in health and wellness, especially after surgical procedures. Incorporating pain relief directly into garments offers a new approach to improving recovery for patients and caregivers, signaling the need to move past traditional recovery methods, Schindler says.

]]> Emsculpt Neo Approved for Medical and Aesthetic Use https://plasticsurgerypractice.com/treatment-solutions/products/emsculpt-neo-approved-for-medical-and-aesthetic-use/ Wed, 09 Oct 2024 16:23:50 +0000 https://plasticsurgerypractice.com/?p=121089 Summary: BTL’s Emsculpt Neo has received FDA clearance to stimulate neuromuscular tissue in the legs and arms for rehabilitation, expanding its original use for fat reduction and muscle building to now address medical conditions and improve patients’ mobility and recovery.

Key Takeaways

  1. Emsculpt Neo has received FDA clearance to stimulate neuromuscular tissue in the legs and arms for rehabilitation purposes.
  2. The device is now approved for preventing disuse atrophy, muscle re-education, increasing range of motion, and improving circulation.
  3. Its application extends to post-surgery recovery, mobility improvement, and injury prevention for various patients, including the elderly and athletes.

————————————————————————————————————————————————

BTL announces that Emsculpt Neo has nabbed U.S. FDA clearance to stimulate neuromuscular tissue in the legs and arms for rehabilitation. Originally launched in 2020 for fat reduction and muscle building, Emsculpt Neo now expands in 2024 to address medical conditions, with the goal of enhancing patients’ quality of life.

Boosting Mobility and Enhances Circulation

Emsculpt Neo is now cleared for preventing disuse atrophy, muscle re-education, increasing range of motion, preventing post-surgical calf muscle thrombosis, relaxing muscle spasms, and enhancing local circulation.

“Emsculpt Neo not only improves appearance but also function,” says Mohamed M. Abdulhamid, MD, FAANS, a board-certified neurosurgeon specializing in minimally invasive spine surgery. “Its abilities have changed my patients’ lives, helping them regain strength and mobility after surgery where traditional therapy fell short. Watching them recover confidence and movement was transformative.”

Addressing Medical and Aesthetic Needs

The application of Emsculpt Neo now spans rehabilitation after surgery, individuals seeking improved mobility and flexibility, older adults addressing age-related decline, recreational athletes looking to prevent injuries, and professional athletes managing muscle strain. With over 4 million treatments performed, Emsculpt Neo continues to deliver outcomes for muscle building and fat reduction.

“This FDA clearance opens new possibilities for Emsculpt Neo, bringing more patients into care,” said Rohit Mishra, director of product management. “We are focused on evolving this platform to meet the demands of both medical and aesthetic needs.”

]]> CollPlant, Stratasys Explore 3D-Printed Breast Implants https://plasticsurgerypractice.com/client-objectives/aesthetics/breast-augmentation/collplant-stratasys-explore-3d-printed-breast-implants/ Fri, 23 Aug 2024 16:53:37 +0000 https://plasticsurgerypractice.com/?p=120935 Summary: CollPlant Biotechnologies and Stratasys Ltd. have initiated a pre-clinical study to develop 3D-printed regenerative breast implants that promote natural tissue growth and biodegrade over time.

Key Takeaways

  1. Innovative Collaboration: CollPlant Biotechnologies and Stratasys Ltd. are collaborating to develop 3D-printed regenerative breast implants using CollPlant’s bioinks and Stratasys’ Origin printer. This partnership aims to scale up bioprinting solutions for the $3 billion breast implant market.
  2. Regenerative Potential: The 200cc implants, currently under pre-clinical study, are designed to promote natural breast tissue growth and biodegrade completely over time, offering a potential alternative to traditional silicone implants with the added benefit of not triggering an immune response.
  3. Promising Pre-Clinical Results: Early pre-clinical data shows that the implants support tissue regeneration and initial biodegradation without adverse reactions, indicating the implants’ safety and effectiveness. The first study results are expected in the first half of 2025.

——————————————————————————————————————————————————

CollPlant Biotechnologies and Stratasys Ltd. launched a pre-clinical study using 200cc regenerative implants, 3D-printed with CollPlant’s bioinks on a Stratasys Origin printer. The collaboration is focused on developing and scaling up bioprinting solutions for breast implants. The study will assess the implants’ ability to promote natural breast tissue growth and their potential for complete biodegradation over time.

Regenerative Breast Tissue Implants

CollPlant’s breast implants are designed to regenerate natural breast tissue without triggering an immune response and could serve as an alternative for reconstructive and aesthetic procedures in the $3 billion breast implant market.

“This pre-clinical study marks a significant step forward in our effort to provide patients with care using regenerative medicine instead of traditional implants,” says Stratasys CEO Yoav Zeif, PhD. “CollPlant’s work is truly inspiring, and our collaboration exemplifies how Stratasys partners with customers to push the timeline and the boundaries of innovation. Together, we are driven by a shared mission to challenge the status quo and find new ways to improve lives and advance healthcare.”

High-Resolution Regenerative Implants

CollPlant CEO Yehiel Tal also spoke out about the pre-clinical study, commenting: “We are extremely happy about the progress we’ve made with our breast implants program, and with Stratasys’ successful achievement to develop a printer that enables us to print a commercial-size implant with high resolution and optimal physical properties. The combined pioneering technologies of both companies is expected to streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants.”

“We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer, thereby significantly improving patient outcomes,” Tal adds.

Since their collaboration began in April 2023, Stratasys has adapted the Origin printer to produce 200cc regenerative implants, which CollPlant has successfully 3D-printed. Initial study results are expected in the first half of 2025.

Earlier this year, CollPlant reported data from ongoing pre-clinical studies showing well-developed connective tissue and blood vessels forming within the implant. Tissue regeneration and initial biodegradation were observed, with the implant’s structure remaining intact. No adverse tissue reactions were detected, indicating the implant’s safety.

]]> InMode Expands Aesthetic Solutions with QuantumRF Technology https://plasticsurgerypractice.com/treatment-solutions/products/inmode-expands-aesthetic-solutions-with-quantumrf-technology/ Thu, 15 Aug 2024 13:03:21 +0000 https://plasticsurgerypractice.com/?p=120921 Summary: InMode Ltd. has introduced IgniteRF, a minimally invasive system with nine technologies for soft-tissue contraction, along with the QuantumRF product line for targeted aesthetic treatments.

Key Takeaways

  • QuantumRF, part of the IgniteRF platform, offers fractionated radiofrequency for deeper tissue targeting, designed for both small and large treatment areas without the need for surgery.
  • Radiofrequency (RF) technology is favored in aesthetics for its effectiveness in stimulating collagen production, promoting tissue remodeling, and offering quicker recovery times compared to surgical procedures.

——————————————————————————————————————————————————

InMode Ltd. has introduced IgniteRF, a minimally invasive system with nine technologies designed for soft-tissue contraction at various depths.

Targeting Deep Tissue Layers

The IgniteRF platform, along with BodyTite, FaceTite, Morpheus8, and the new QuantumRF product line, provides a suite of radiofrequency solutions for different aesthetic and surgical needs. QuantumRF is a minimally invasive technology that uses fractionated radiofrequency to target deeper tissue layers. The QuantumRF 10 and QuantumRF 25 cannulas are designed for smaller and larger treatment areas, respectively, allowing for results without the need for invasive surgery.

Radiofrequency (RF) technology is recognized in the aesthetics industry for its effectiveness and safety, with procedures that are minimally or non-invasive. RF treatments heat deeper skin layers to stimulate collagen production and promote tissue remodeling, leading to firmer skin and a more youthful appearance. RF is preferred in aesthetics for its consistent and noticeable results, minimal discomfort, and quick recovery times compared to surgical procedures.

“IgniteRF marks a significant milestone for InMode, with continued innovation to make our technology faster, smarter, and even more effective,” says Michael Kreindel, MD, chief technology officer and co-founder of InMode.

Advancing Skin Retraction

Alfredo Hoyos, MD, a board-certified plastic surgeon from Bogota, Colombia, known for his work in body contouring, has completed over 100 QuantumRF procedures. He is the creator of the High Definition Liposculpture technique and related procedures.

 “QuantumRF is a significant advancement in skin retraction technology. Its internal bipolar system and fractional delivery make procedures faster and more efficient, up to seven times more so than other devices,” Hoyos adds. “With QuantumRF, we have the best product available today, combining safety, efficiency, and unparalleled results.”

]]> FzioMed to Showcase Dynavisc Adhesion Barrier Product https://plasticsurgerypractice.com/treatment-solutions/wound-care/fziomed-to-showcase-dynavisc-adhesion-barrier-product/ Mon, 17 Jun 2024 21:32:52 +0000 https://plasticsurgerypractice.com/?p=120807 Summary: FzioMed Inc. will showcase its Dynavisc adhesion barrier gel at the FESSH congress in Rotterdam from June 26 to 29. The gel, used to reduce adhesions in tendon and peripheral nerve surgeries, and as the company explains, it does not migrate after application as its unique viscosity is flowable yet remains where applied.

Key Takeaways:

  • The company’s synthetic adhesion barrier products are based on the company’s patented dual-polymer formulation and more than 20 years of clinical use. 
  • Dynavisc adhesion barrier gel is provided sterile and ready to use with a smooth, rounded tip applicator that allows for ease of application while the clear gel formula maintains local visibility.

FzioMed Inc, a company offering post-surgical adhesion prevention products, announced it will attend the Federation of European Societies for the Surgery of the Hand (FESSH) congress June 26 to 29 in Rotterdam, The Netherlands, and showcase its Dynavisc adhesion barrier gel. The gel is designed to reduce the formation of adhesions following tendon and peripheral nerve related surgical procedures. 

According to a press release from FzioMed, its synthetic adhesion barrier products are based on the company’s patented dual-polymer formulation and more than 20 years of clinical use. They provide a temporary, mechanical separation of tissues during the normal healing process, reducing adhesion formation. For tendon and peripheral nerve related surgical procedures, Dynavisc gel and its unique applicator offer ease of use combined with proven safety and clinical efficacy, says the company.

Franco Bassetto, MD, professor of plastic, reconstructive and aesthetic surgery and chief of the plastic surgery clinic, Padova University Hospital, Italy, will be presenting a lecture on Friday, June 28 at 11:30 CEST titled “The Efficacy of Carboxymethylcellulose-Polyethylene Oxide Gel in Zone II Flexor Tendon Injury: From Urgency to Revision Surgery” where he will discuss the results of a clinical study utilizing Dynavisc. Prof. Bassetto will also be available at FzioMed’s exhibitor booth periodically throughout the congress to speak about his clinical experience with Dynavisc adhesion barrier gel.

“Even with the best surgical technique, post-operative adhesions can form following tendon and peripheral nerve procedures, including flexor tendon repair, tenolysis, Dupuytren’s contracture, neurolysis and carpal tunnel syndrome,” stated Roberta Lojacono, director of sales—EMEA. “These adhesions can cause post-operative pain and complications such as limited range of motion.”

According to the company, Dynavisc adhesion barrier gel is provided sterile and ready to use with a smooth, rounded tip applicator that allows for ease of application while the clear gel formula maintains local visibility. No special storage, refrigeration, mixing, or handling is required. As the company explains, Dynavisc gel does not migrate after application as its unique viscosity is flowable yet remains where applied. 

FzioMed’s portfolio of adhesion barrier products has been available since 2002 and have been used in nearly 1 million procedures worldwide.

]]> GC Aesthetics Unveils MDR-Approved Breast Implant https://plasticsurgerypractice.com/client-objectives/aesthetics/breast-augmentation/gc-aesthetics-unveils-mdr-approved-breast-implant/ Wed, 24 Apr 2024 00:32:47 +0000 https://plasticsurgerypractice.com/?p=120614 Key Takeaways
  1. The Introduction of Luna XT marks a milestone as the first MDR-approved breast implant, reflecting a shift toward enhanced safety standards in the medical field.
  2. Escalating numbers of breast reconstruction surgeries underscore the demand for MDR-approved products, highlighting the importance of stringent safety standards.
  3. Luna XT is designed to meet diverse patient needs in breast reconstruction surgery.

________________________________________________________________________________________________________________

Breast implant provider GC Aesthetics (GCA) has introduces Luna XT, the first breast implant approved under the new European Medical Device Regulation (MDR). GCA officials say these regulations prioritize product safety, transparency, and clinical evidence, marking a significant shift in medical standards.

Rising Number of Breast Reconstruction Surgeries

The demand for MDR-approved products, devices, and implants is underscored by the escalating numbers of breast reconstruction surgeries. According to the NHS website, the UK witnessed 2,100 breast reconstruction surgeries in 2022, with a further 460 procedures carried out through independent/private clinics. This marks a notable 36% increase since 2017, highlighting the necessity for products adhering to stringent safety standards outlined in the new MDR.

The Luna XT Anatomical Breast Implant is designed to support women undergoing immediate and delayed breast reconstruction surgery. It features a microtextured surface, cohesive silicone gel, and high-performance shell, reflecting advancements in the field. Luna XT is available in different projections, heights, and volumes to meet various patient needs.

First MDR-Certified Breast Implant

Carlos Reis Pinto, CEO at GC Aesthetics, endorsed Luna XT, stating: “Being the first to launch the first MDR-approved breast implant in the market is a testimonial of GC Aesthetics’ commitment to women’s healthcare and safety. MDR rules have been designed to improve product safety ensuring greater openness, traceability, and clinical safety evidence. Having the first breast implant manufacturing system in the world certified under the new MDR rules demonstrates that our company continues to pursue excellence and customer satisfaction.” 

Fara Naomi Macías, chief marketing officer of GCA, also spoke out about Luna XT: “It is GC Aesthetics’ commitment to offer a strong and comprehensive portfolio of products for women. We are committed to delivering safe options that establish a newer, higher, and more beneficial standard of care for women who seek to recover their breast and nipple shape, look, and feel.”

]]> Elevai Labs Acquires Global License Agreement for Proprietary Stem Cell Manufacturing Technology   https://plasticsurgerypractice.com/news/company-news/elevai-labs-acquires-global-license-agreement-for-proprietary-stem-cell-manufacturing-technology/ Tue, 16 Jan 2024 23:14:32 +0000 https://plasticsurgerypractice.com/?p=120408 Elevai Labs Inc, a medical aesthetic company specializing in physician-dispensed skincare, announced it has signed an  exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio Inc. The licensing agreement grants Elevai a license to use INmune Bio’s proprietary “EMx” technology, developed by INmune Bio’s Chief Manufacturing Officer Mark Lowdell, PhD. This reportedly will allow Elevai to manufacture current Good Manufacturing Practice (cGMP) grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed  topical cosmetic products sold in the medical aesthetics skincare market. 

In a press release from Elevai, it says it believes incorporating the EMx technology into its operations is a step towards the company’s goal of achieving vertical manufacturing integration, while also expanding long term production capabilities and lowering overall costs. Ultimately, Elevai says it believes controlling its processes through its product pipeline with what it believes to be efficient technologies like  EMx will allow greater stem cell consistency, purity, and propel Elevai’s branded cosmetic  products further to maintain the company’s position as an industry innovator in the medical aesthetics skincare market. 

Jordan R. Plews, PhD, CEO of Elevai Labs Inc, said of the agreement, “Partnering with INmune Bio Inc.aligns perfectly with our mission to pioneer innovative stem cell exosome products. Their understanding of efficient human stem cell isolation and large-scale manufacturing provides us with a remarkable opportunity to expand our manufacturing  capabilities, expand our product portfolio, and make a significant impact in the market.” 

]]>